Skip to main content

Table 1 Mechanisms of ferroptosis in urological cancers

From: Roles of ferroptosis in urologic malignancies

Cancer type

Biomolecular mechanism


Prostate cancer

HDECR1 silencing induced ferroptosis by accumulation of PUFAs and then promoting ROS generation


Silencing of PANX2 promoted ferroptosis by suppressing the expression of Nrf2


PI3K/AKT/mTOR inhibited ferroptosis via upregulating SREBP1/SCD1


HSPB1inhibited ferroptosis by promoting iron uptake and increasing lipid ROS production


Bicalutamide-iron combination induced ferroptosis


The combination of erastin and docetaxel induced ferroptosis


CHAC1 inhibits cell viability and increases the sensitivity of prostate cancer cells to docetaxel by inducing ferroptosis


Therapy-induced lipid uptake and remodeling underpin GPX4 dependence and ferroptosis hypersensitivity


Kidney cancer

VHL/HIF-2α induced ferroptosis via elevating lipid peroxidation levels through HILPDA


TAZ silencing reduce sensitivity to erastin-induced ferroptosis by downregulating the expression of EMP1-NOX4


ACOT8 inhibited ferroptosis


Repression of SUV39H1 induced ferroptosis via enhancing DPP4 activity


The low-expression of NCOA4 conferred ccRCC cells resistance to ferroptosis by increasing FTH and FTMT expression levels


GPX1 induced ferroptosis in KIPP


ART induced ferroptosis and enhanced the anti-tumor effect of sunitinib

[118, 119]

Bladder cancer

CPNPs targeted to EDNRB via EDN3-CPNPs and thereby induced ferroptosis


Quinazolinyl-arylurea derivatives induced ferroptosis through ROS generation and GSH depletion